Report Highlights

U.S. Point of Care Glucose Testing: Market Overview

The U.S. point of care glucose testing market is the largest single-country segment globally, accounting for roughly 38% of worldwide POC glucose revenue in 2024. Its scale reflects a confluence of factors unique to the American healthcare system: an estimated 38.4 million diagnosed diabetic adults, a fragmented payer structure that accelerates decentralized diagnostics, and a hospital system where bedside glucose monitoring is a mandated component of glycemic management protocols under Joint Commission standards. The market spans self-monitoring blood glucose devices, hospital-grade handheld analyzers, and the rapidly expanding connected glucometer segment tied to digital health platforms.

Unlike most global markets, the U.S. POC glucose landscape is bifurcated between the retail consumer channel — dominated by pharmacy chains such as CVS and Walgreens — and the institutional channel covering hospitals, long-term care facilities, and physician offices. Institutional accounts represent approximately 44% of total revenue but generate disproportionate strip volume due to frequency-of-testing protocols. The market structure is oligopolistic at the device level, with Abbott, Roche, and Ascensia controlling over 70% of installed base, while the consumables (test strips) segment drives recurring revenue and sustains the competitive moat for incumbents through proprietary cartridge lock-in.

Growth Drivers in the U.S. Point of Care Glucose Testing Market

Three structural demand drivers sustain market expansion through 2032. First, the Centers for Disease Control and Prevention estimates that 96 million Americans have prediabetes, a population increasingly targeted by preventive testing programs. The National Diabetes Prevention Program, funded through CMS and the CDC, has enrolled over 500,000 participants since 2018, each of whom represents a conversion pathway to regular glucose monitoring. Second, the 21st Century Cures Act mandates interoperability of health data, pushing healthcare systems toward connected POC devices that transmit glucose readings directly into electronic health records — a requirement that is accelerating institutional device refresh cycles nationwide.

Third, the CMS Inpatient Prospective Payment System creates strong financial incentives for hospitals to manage glycemic outcomes precisely, as hyperglycemia-related complications trigger readmission penalties. The American Diabetes Association's hospital glycemic management guidelines explicitly recommend POC glucose testing at defined intervals for all insulin-treated inpatients, embedding strip consumption into standard care protocols. Additionally, the expansion of Medicaid under the Affordable Care Act added over 21 million previously uninsured Americans, many with undiagnosed diabetes, directly enlarging the addressable testing population across both retail and clinic-based channels.

Market Restraints and Entry Barriers

The FDA's 510(k) clearance pathway for POC glucose devices is demanding by global standards. Devices must demonstrate analytical accuracy meeting ISO 15197:2013 criteria, and since 2016 the FDA has applied additional Special Controls guidance requiring clinical studies with diverse patient populations. This pathway typically requires 12 to 18 months and USD 1.5 million to USD 4 million in regulatory and clinical costs before a single unit ships commercially. Foreign manufacturers seeking U.S. market entry must also register manufacturing facilities with the FDA under 21 CFR Part 820, and any Quality System Regulation deficiency triggers an import alert that can halt product at the border indefinitely — a risk that has deterred several Asian competitors.

Incumbent advantages in the institutional channel are compounded by Group Purchasing Organization dynamics. Over 96% of U.S. hospitals participate in GPOs such as Vizient, Premier, or HealthTrust, which negotiate multi-year supply contracts that effectively foreclose new entrants from acute care accounts for contract cycle durations of three to five years. In the retail channel, the CMS competitive bidding program for diabetes supplies under the Medicare Diabetic Supplies benefit has compressed strip reimbursement rates by over 70% since 2013, making low-volume entrants economically unviable without scale. These combined regulatory and commercial barriers create a market structure that rewards existing volume leaders and penalizes late arrivals.

Market Opportunities in the U.S. Point of Care Glucose Testing Market

The most immediately actionable opportunity lies in the long-term care segment, where an estimated 1.4 million skilled nursing facility residents require routine glucose monitoring, yet facility-level device standardization remains fragmented. National long-term care pharmacy providers such as Omnicare and PharMerica are consolidating purchasing, creating an opening for vendors offering integrated strip-device-software bundles with outcomes reporting dashboards. This subsegment represents an addressable market of approximately USD 420 million annually and is underserved by the three major incumbents, whose sales force structures are weighted toward acute care hospital systems rather than post-acute channels.

A second high-growth opportunity exists in pharmacy-based chronic disease management programs, accelerated by CMS's expansion of Medicare Annual Wellness Visit billing codes and the growth of pharmacist-led diabetes care programs under collaborative practice agreements now legal in 48 states. Chains including Walmart Health and CVS MinuteClinic are deploying POC testing stations at scale, with Walmart Health alone targeting 4,000 clinic locations by 2030. Vendors that can offer CLIA-waived, EHR-connected glucose testing devices at a per-test cost below USD 0.85 — the threshold at which pharmacy operators achieve margin-positive outcomes — will capture preferred vendor status in this rapidly expanding channel.

Market at a Glance

Leading Market Participants

• Abbott Laboratories
• Roche Diagnostics
• Ascensia Diabetes Care (Bayer heritage)
• Dexcom
• Nova Biomedical
• Trividia Health
• AgaMatrix
• Senseonics Holdings
• LifeScan (Johnson and Johnson heritage)
• Arkray USA

Regulatory and Policy Environment

POC glucose devices in the U.S. are regulated as Class II medical devices under 21 CFR Part 862, with market entry requiring FDA 510(k) clearance under product code NBW. The FDA's 2016 Guidance Document "Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use" established Special Controls that mandate specific clinical study designs, system accuracy thresholds, and labeling requirements for healthcare professional-use devices. Separately, all POC glucose testing performed outside of a CLIA-certified laboratory must comply with the Clinical Laboratory Improvement Amendments of 1988 (CLIA), specifically 42 CFR Part 493, which classifies most handheld glucose meters as CLIA-waived under specific conditions — a designation that must be obtained from CMS independently of FDA clearance.

From a reimbursement standpoint, Medicare coverage for self-monitoring blood glucose supplies is governed by the Medicare Benefit Policy Manual, Chapter 15, Section 111.1. CMS's National Competitive Bidding Program, operating under the Medicare Durable Medical Equipment benefit, has established maximum reimbursement rates for test strips in nine competitive bidding areas, with 2023 rates averaging USD 0.33 per strip — a 73% reduction from pre-competitive bidding levels. The Inflation Reduction Act of 2022 indirectly supports market growth by capping insulin out-of-pocket costs at USD 35 per month for Medicare beneficiaries, reducing a key barrier to diabetes management adherence and sustaining demand for glucose monitoring across the Medicare population.

Long-Term Outlook for U.S. Point of Care Glucose Testing

By 2032, the U.S. POC glucose testing market will be structurally divided between a high-volume, low-margin strip consumables segment and a higher-margin connected device and data analytics layer. Incumbents who successfully monetize glucose data through software subscriptions — as Abbott is pursuing through the LibreView platform — will decouple revenue growth from unit volume. Hospital-grade POC glucose systems will increasingly integrate with AI-driven insulin dosing decision support tools, a convergence already demonstrated by Glytec's Glucommander platform embedded in systems using Nova StatStrip devices, making device switching in institutional settings significantly more disruptive than today.

The demographic trajectory is unambiguous: the U.S. diabetic population is projected to reach 54.9 million by 2030 per American Diabetes Association modeling, sustaining baseline demand regardless of CGM penetration rates. However, market concentration will intensify as GPO contract consolidation continues and FDA enforcement of quality system regulations creates additional barriers for smaller players. Vendors without a connected device strategy and without a long-term care channel will find their addressable market shrinking to the retail self-pay segment — a segment compressed by both competitive bidding and CGM substitution. The market rewards scale, regulatory expertise, and channel breadth simultaneously.